Clinical research in cardiology : official journal of the German Cardiac Society · 2026
Interleukin-8 and other neutrophil-related biomarkers are associated with 1-year mortality in patients with acute myocardial infarction.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Yu-Jen, Matter Michael A, Rossi Valentina A, Heg Dik, Costantino Sarah, Paneni Francesco, Gallino Camilla, Stähli Barbara E, Räber Lorenz, Windecker Stephan, Mach François, Gencer Baris, Klingenberg Roland, Rodondi Nicolas, Nanchen David, Levesque Mitchell P, Demler Olga V, Ruschitzka Frank, Matter Christian M
Аннотация
BACKGROUND: Interleukin-8 (IL-8) triggers early inflammatory responses upon tissue injury, activating neutrophils that release neutrophil extracellular traps with cell-free DNA (cfDNA) and myeloperoxidase (MPO). Injury upon acute myocardial infarction (AMI) induces an early excessive inflammatory response. The value of IL-8 and neutrophil-related biomarkers for AMI patient outcomes is incompletely understood.
METHODS: AMI patients sampled ≤ 24 h after symptom onset were included from SPUM-ACS cohort. One hundred twelve cases with all-cause mortality or recurrent AMI within 1 year were matched 1:1 to event-free controls by age, sex, AMI subtype, symptom onset time, and recruiting sites.
RESULTS: Cases showed higher IL-8 (median: 66.82 vs. 41.24 pg/mL; p = 0.001), cfDNA (393.9 vs. 223.8 ng/mL; p < 0.001), MPO (683.4 vs. 602.2 ng/mL; p = 0.030), and neutrophil-to-lymphocyte ratio (NLR) than controls (6.22 vs. 4.76; p = 0.013). IL-8 and cfDNA were higher in the death subgroup than recurrent AMI (IL-8: 71.16 vs. 51.52 pg/mL; p = 0.026; cfDNA: 420.5 vs. 239.7 ng/mL; p = 0.030). Notably, IL-8 peaked in the hyper-acute phase (< 6 h), earlier than high-sensitivity troponin T (hsTnT). This aligned with its associations with death or recurrent AMI (OR = 1.62; p = 0.021), death (OR = 2.14; p = 0.019), and early presenters (< 6 h, OR = 2.65; p = 0.008) after adjusting for confounders (estimated glomerular filtration rate [eGFR], high-sensitivity C-reactive protein [hsCRP], N-terminal pro-B-type natriuretic peptide [NT-proBNP], and hsTnT). IL-8, along with cfDNA, NLR, and hsCRP clustered in patients with increased Killip Class and worse outcomes.
CONCLUSIONS: IL-8 and neutrophil-related biomarkers were associated with 1-year mortality in AMI patients, especially in the hyper-acute phase.
CLINICAL TRIAL REGISTRATION: NCT01000701.
METHODS: AMI patients sampled ≤ 24 h after symptom onset were included from SPUM-ACS cohort. One hundred twelve cases with all-cause mortality or recurrent AMI within 1 year were matched 1:1 to event-free controls by age, sex, AMI subtype, symptom onset time, and recruiting sites.
RESULTS: Cases showed higher IL-8 (median: 66.82 vs. 41.24 pg/mL; p = 0.001), cfDNA (393.9 vs. 223.8 ng/mL; p < 0.001), MPO (683.4 vs. 602.2 ng/mL; p = 0.030), and neutrophil-to-lymphocyte ratio (NLR) than controls (6.22 vs. 4.76; p = 0.013). IL-8 and cfDNA were higher in the death subgroup than recurrent AMI (IL-8: 71.16 vs. 51.52 pg/mL; p = 0.026; cfDNA: 420.5 vs. 239.7 ng/mL; p = 0.030). Notably, IL-8 peaked in the hyper-acute phase (< 6 h), earlier than high-sensitivity troponin T (hsTnT). This aligned with its associations with death or recurrent AMI (OR = 1.62; p = 0.021), death (OR = 2.14; p = 0.019), and early presenters (< 6 h, OR = 2.65; p = 0.008) after adjusting for confounders (estimated glomerular filtration rate [eGFR], high-sensitivity C-reactive protein [hsCRP], N-terminal pro-B-type natriuretic peptide [NT-proBNP], and hsTnT). IL-8, along with cfDNA, NLR, and hsCRP clustered in patients with increased Killip Class and worse outcomes.
CONCLUSIONS: IL-8 and neutrophil-related biomarkers were associated with 1-year mortality in AMI patients, especially in the hyper-acute phase.
CLINICAL TRIAL REGISTRATION: NCT01000701.